Prospectively: Dose 4 may be administered as early as age 12 months if at least 6 months have elapsed since dose 3. ĭiphtheria, tetanus, and pertussis (DTaP) vaccination (minimum age: 6 weeks ) Routine vaccination All routine child and adolescent vaccines are covered by VICP except for pneumococcal polysaccharide vaccine (PPSV23). The National Vaccine Injury Compensation Program (VICP) is a no-fault alternative to the traditional legal system for resolving vaccine injury claims. For information about vaccination in the setting of a vaccine-preventable disease outbreak, contact your state or local health department. Itasca, IL: American Academy of Pediatrics, 2018:67–111). Red Book: 2018 report of the Committee on Infectious Diseases. For vaccination of persons with immunodeficiencies, see Table 8-1, Vaccination of persons with primary and secondary immunodeficiencies, in General Best Practice Guidelines for Immunization, and Immunization in Special Clinical Circumstances (In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Information on travel vaccination requirements and recommendations is available at. For further details, see Table 3-1, Recommended and minimum ages and intervals between vaccine doses, in General Best Practice Guidelines for Immunization. The repeat dose should be spaced after the invalid dose by the recommended minimum interval. Doses of any vaccine administered ≥5 days earlier than the minimum age or minimum interval should not be counted as valid and should be repeated as age-appropriate. Vaccine doses administered ≤4 days before the minimum age or interval are considered valid. 
Within a number range (e.g., 12–18), a dash (–) should be read as “through.”. Intervals of ≥4 months are determined by calendar months. For calculating intervals between doses, 4 weeks = 28 days. For information on contraindications and precautions for the use of a vaccine, consult the General Best Practice Guidelines for Immunization and relevant ACIP statements. Consult relevant ACIP statements for detailed recommendations. See the COVID-19 Vaccine Product Information page for additional information about COVID-19 vaccines authorized for use in the United States. COVID-19 vaccine and other vaccines may be administered on the same day. 
(MenACWY-D ≥9 mos, MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years)ĪCIP recommends use of COVID-19 vaccines for everyone ages 12 and older within the scope of the Emergency Use Authorization for the particular vaccine. Tetanus, diphtheria, & acellular pertussis (RV) RV1 (2-dose series) RV5 (3-dose series)ĭiphtheria, tetanus, & acellular pertussis
0 kommentar(er)
